Apcin |
| Catalog No.GC18518 |
Apcin, un ligando de Cdc20, es un inhibidor potente y competitivo de la actividad de la ligasa E3 del complejo promotor de la anafase/ciclosoma (APC/C(Cdc20)). Apcin inhibe competitivamente la ubiquitilaciÓn dependiente de APC/C al unirse a Cdc20 y prevenir el reconocimiento del sustrato. Apcin ocupa el bolsillo de uniÓn de la caja D en la cara lateral del dominio WD40 y puede prolongar la mitosis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 300815-04-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Apcin is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C). Apcin competitively binds to Cdc20 and prevents substrate interaction and ubiquitylation required for continuation of mitosis. Apcin enhances the effect of the APC/C inhibitor N-4-tosyl-L-arginine methyl ester and its prodrug, proTAME, leading to an increase in the number of cells in mitosis, a longer mitotic duration, and greater stabilization of cyclin B1, cycB1-NT, securin, and cyclin A2. Apcin, in combination with proTAME, synergistically increases apoptosis in multiple myeloma cells.
References:
[1]. Sackton, K.L., Dimova, N., Zeng, X., et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C Nature 514(7524), 646-649 (2014).
[2]. Lub, S., Maes, A., De Veirman, K., et al. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells Oncotarget 7(4), 4062-4076 (2016).
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *